Policy

Congress approves government spending bill with increased FDA funding

The Senate early Friday followed the House’s lead early Friday to pass the $1.3 trillion spending bill to fund the government through 30 September.

The White House had indicated that President Donald Trump supports the bill, but he doesn’t seem so certain:

The omnibus bill would bring the FDA budget to a total of $2.9 billion in discretionary funding (meaning not user fees), $135 million above the 2017 enacted level, according to the House Appropriations Committee.

According to the Alliance for a Stronger FDA, compared to the last FY 2018 continuing resolution, the omnibus would add $41 million in additional discretionary funding.

Of the new funds, $15 million will go toward FDA’s new Oncology Center of Excellence, while the bill also appropriates $60 million to accelerate medical product development as authorized in the 21st Century Cures Act, which is an increase of $40 million available under the Act from 2017.

In addition, a one-time funding of $94 million will help expand FDA’s efforts at International Mail Facilities to address the opioid crisis.

For the NIH and the CDC, the spending bill would provide additional funds as well.

According to the House Appropriations Committee, the bill provides a total of $37 billion for NIH, an increase of $3 billion above the FY 2017 enacted level.

The bill also increases funding for several research initiatives, including:

  • $1.8 billion (+$414 million) for Alzheimer’s disease research
  • $400 million (+$140 million) for the Brain Research through Application of Innovative Neurotechnologies (BRAIN) initiative
  • $290 million (+$60 million) for the All of Us research initiative (formerly called the Precision Medicine Initiative)
  • $10 million (+$8 million) for regenerative medicine research
  • $100 million (+$40 million) for universal flu vaccine research
  • $351 million (+17 million) for research on combating antibiotic-resistant bacteria
  • $543 million (+27 million) for Clinical and Translational Science Awards
  • $351 million (+$17 million) for Institutional Development Awards (IDeA).

First published here. Regulatory Focus is the flagship online publication of the Regulatory Affairs Professionals Society (RAPS), the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Email news@raps.org for more information.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->